Steno Diabetes Center Odense, Denmark, evaluates Diabetic Foot Screening for clinical use
The Diabetes Clinic at Steno Diabetes Center Odense, Denmark, has begun an evaluation of the VibroSense Meter® II with Diabetic Foot Screening as part of testing a new process to optimize patient flow.
Steno Diabetes Center, Odense has started a project to optimize patient flow as part of implementing a "One Stop Shop" concept, with the aim of minimizing the number of hospital visits for regular health checks of people living with diabetes.
If the outcome of the evaluation is approved, the new concept can be implemented in the regions' other hospitals, which in that case entails additional needs for VibroSense Meter II. The evaluation is expected to be completed within 6 to 8 months.
"We look forward to the project at Steno Diabetes Center Odense with excitement. With a positive outcome, there are good possibilities for Diabetic Foot Screening to also be introduced at Steno's other diabetes centers throughout Denmark and associated regions," says Hans Wallin, CEO VibroSense Dynamics AB.
About Steno Diabetes Center Odense
The Novo Nordisk Foundation has since a few years started seven Steno Diabetes Centers in collaboration with Denmark's five regions as well as the Faroe Islands and Greenland. The overall goal of these centers is to research and develop knowledge about the care of people living with diabetes. The goal is also to be regional knowledge centers as a support to the regions' other diabetes clinics.
Steno Diabetes Center Odense (SDCO) was started in 2018 at Odense University Hospital. The center has a special focus on type 2 diabetes, including research, prevention, detection, treatment of late complications and education of healthcare professionals. Through collaborations with other hospitals and healthcare providers in the region, SDCO aims to play a major role in developing and improving diabetes care throughout southern Denmark.
The Novo Nordisk Foundation has committed up to DKK 1.4 billion (€188 million) to SDCO. The funding period extends to 2027, with possible extension thereafter
Contact
Hans Wallin, CEO VibroSense Dynamics AB
Tel: +46 40 88 026
Email: [email protected]
www.vibrosense.com
"The new Gold Standard for reliable
detection of nerve damage"
About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve damage in the hands and feet. The method involves measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.
Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can implement preventive measures that prevent, reduce or delay the onset of nerve damage in the hands and feet.
